| Name | Title | Contact Details |
|---|
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.
Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company`s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company`s lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment of both seasonal and pandemic influenza, is in a phase 2a clinical trial and expected to enter a phase 2b clinical trial by year end 2017. The company`s second product candidate, VIS649, is a monoclonal antibody engineered to treat IgA nephropathy, a rare chronic kidney disease. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion`s lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.